Review
Biochemistry & Molecular Biology
Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu
Summary: Antibodies targeting PD-1/PD-L1 revive immune response against cancer cells, but the low response rate calls for combination therapies. Combining with chemotherapy, radiotherapy, and other treatments can achieve better outcomes, and individualized combination selection is needed to overcome treatment resistance.
Article
Multidisciplinary Sciences
Xin Guan, Liping Sun, Yuting Shen, Fengshan Jin, Xiaowan Bo, Chunyan Zhu, Xiaoxia Han, Xiaolong Li, Yu Chen, Huixiong Xu, Wenwen Yue
Summary: Surgical resection often leads to tumor recurrence, impacting clinical outcomes. Novel nanosystem utilizing manganese dioxide shows promise in reducing cancer recurrence and metastasis post-surgery by targeting myeloid cells and relieving tumor hypoxia, ultimately enhancing response to radio-immunotherapy.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Yuqing Zhou, Zhaoxia Liu, Tingtao Chen
Summary: In recent decades, immunotherapy, especially PD1/PD-L1 inhibitors, has shown great potential in cancer treatment. However, its application is restricted due to unexpected toxicities, limited response rate, and resistance. Fortunately, gut microbiome has been found to play a crucial role in anti-PD1/PD-L1 therapy, offering a possible solution to enhance clinical efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Nitin Roper, Moises J. Velez, Alberto Chiappori, Yoo Sun Kim, Jun S. Wei, Sivasish Sindiri, Nobuyuki Takahashi, Deborah Mulford, Suresh Kumar, Kris Ylaya, Christopher Trindade, Irena Manukyan, Anna-Leigh Brown, Jane B. Trepel, Jung-Min Lee, Stephen Hewitt, Javed Khan, Anish Thomas
Summary: This study identifies elevated Notch signaling as a significant predictor of clinical benefit in immune checkpoint blockade (ICB) for relapsed small cell lung cancer (SCLC) patients. Activation of Notch signaling induces a low NE phenotype, leading to increased expression of antigen processing and presentation machinery (APM) genes and improved intrinsic tumor immunity.
NATURE COMMUNICATIONS
(2021)
Article
Chemistry, Multidisciplinary
Yang Sun, Liuting Mo, Xiaoxiao Hu, Die Yu, Sitao Xie, Jianglin Li, Zilong Zhao, Xiaohong Fang, Mao Ye, Liping Qiu, Weihong Tan, Yu Yang
Summary: This study reported a bispecific aptamer that improved T-cell immune response and induced a potent immunological effect against tumors through a recognition-then-conjugation strategy.
Article
Engineering, Biomedical
Yunjian Yu, Jie Li, Boyi Song, Zhuang Ma, Yufei Zhang, Haonan Sun, Xiaosong Wei, Yayun Bai, Xueguang Lu, Peng Zhang, Xinge Zhang
Summary: An all synthetic nanoparticle with PD-L1 blockade capability is developed for cancer photothermal-immunotherapy, offering a simple but promising approach for the treatment of metastatic cancer.
Review
Oncology
Xingyu Chen, Lixiang Feng, Yujing Huang, Yi Wu, Na Xie
Summary: Breast cancer, especially triple-negative breast cancer, is difficult to treat due to its resistance to conventional therapy. The use of immunotherapy with programmed death receptor 1 (PD-1) and its ligands has shown potential, but many patients develop resistance. This review discusses the resistance mechanisms and potential strategies to overcome them, improving the therapeutic efficacy of PD-1 and its ligand-based antibodies in triple-negative breast cancer.
Article
Immunology
Tingxuan Gu, Xueli Tian, Yuanyuan Wang, Wenqian Yang, Wenwen Li, Mengqiu Song, Ran Zhao, Mengqiao Wang, Quanli Gao, Tiepeng Li, Chengjuan Zhang, Joydeb Kumar Kundu, Kangdong Liu, Zigang Dong, Mee-Hyun Lee
Summary: Immunotherapy has become an effective treatment for various cancers by blocking immune checkpoint markers, like PD-1 and PD-L1. Pentamidine, an FDA-approved antimicrobial agent, was identified as a small-molecule antagonist of PD-L1. It enhanced T-cell-mediated cytotoxicity against cancer cells by increasing the secretion of immune-related molecules and promoting T-cell activation. In vivo administration of pentamidine inhibited tumor growth and increased the number of tumor-infiltrating lymphocytes. This study suggests that pentamidine could be repurposed as a novel PD-L1 antagonist for small molecule cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Kuang Du, Shiyou Wei, Zhi Wei, Dennie T. Frederick, Benchun Miao, Tabea Moll, Tian Tian, Eric Sugarman, Dmitry Gabrilovich, Ryan J. Sullivan, Lunxu Liu, Keith T. Flaherty, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang
Summary: Researchers have developed pathway-based signatures using transcriptomic data and clinical information to accurately predict responses to anti-PD1 therapy in melanoma, with the PASS-ON signature demonstrating superior performance compared to existing signatures across multiple datasets.
NATURE COMMUNICATIONS
(2021)
Review
Pharmacology & Pharmacy
Dan Zheng, Xiaolin Hou, Jing Yu, Xiujing He
Summary: Immune checkpoint therapy is a promising anti-cancer strategy, but poor response has been observed in metastatic breast cancer. Combination therapy with PD-1/PD-L1 blockade and other standard treatments is expected to overcome this limitation.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Engineering, Biomedical
Nisi Zhang, Wenlong Zeng, Yunxue Xu, Rui Li, Mengxuan Wang, Yijia Liu, Shuai Qu, Katherine W. Ferrara, Zhifei Dai
Summary: In this study, a novel phthalocyanine-conjugated mesoporous silicate nanoparticle (PMSN) is designed for enhancing sonodynamic therapy (SDT) by generating more reactive oxygen species (ROS) and inducing pyroptosis in tumors. The combination with PD-L1 blockade efficiently reduces tumor mass and suppresses residual tumors. Loading chemotherapeutic drugs into PMSN further improves the therapeutic efficacy. This is the first report of SDT-induced pyroptosis in liver cancer, suggesting the potential for clinical translation.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Oncology
Shengchen Su, Sungyong You, Yanping Wang, Patrick Tamukong, Michael J. Quist, Catherine S. Grasso, Hyung L. Kim
Summary: Antitumor immunity requires lymphocytes to localize to the tumor. Prostate cancers (PCs) are immunologically cold and tend to lack T-cell infiltration. Most advanced PCs are insensitive to PD1 blockade therapies.
Article
Biochemistry & Molecular Biology
Lei Sun, Arpad V. Patai, Tara L. Hogenson, Martin E. Fernandez-Zapico, Bo Qin, Frank A. Sinicrope
Summary: Depletion of PD-L1 enhances JNK activity, leading to increased apoptosis and reduced chemotherapy resistance. Degradation of CYLD mRNA by EXOSC10 promotes JNK signaling pathway activation.
Review
Oncology
Zhitao Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Liangliang Wu, Qian Wang, Chengyu Lv, Yichan Zhou, Yongxiang Xia, Weiwei Tang
Summary: Cancer occurrence and development are closely related to immune escape and tolerance of tumor cells. Tumor immunotherapy stimulates and enhances immune function to control tumor cells. Combination immunotherapy has become a hot topic in cancer treatment today.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sophie M. Poznanski, Tyrah M. Ritchie, Isabella Y. Fan, Abdullah El-Sayes, Ana L. Portillo, Ronny Ben-Avi, Eduardo A. Rojas, Marianne Chew, Yaron Shargall, Ali A. Ashkar
Summary: Expanded natural killer (NK) cells from patients with lung cancer can sensitize non-responding tumors to PD1-blockade therapy by maintaining strong antitumor activity against both PDL1+ and PDL1- patient tumors and overcoming tumor-induced immunosuppression, resulting in synergistic tumor destruction when combined with PD1-blockade.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
